NRX Pharmaceuticals (NRXP) Receivables - Other (2023 - 2025)

NRX Pharmaceuticals (NRXP) has 3 years of Receivables - Other data on file, last reported at $3.1 million in Q3 2025.

• On a quarterly basis, Receivables - Other rose 51350.0% year-over-year to $3.1 million in Q3 2025; TTM through Sep 2025 was $3.1 million, a 51350.0% increase from a year earlier, with the FY2023 full-year figure at $6000.0, changed N/A from the prior year.
• Receivables - Other for Q3 2025 stood at $3.1 million, up from $6000.0 in the prior quarter.
• Over the last five years, Receivables - Other for NRXP reached as high as $3.1 million in Q3 2025 and fell as low as $6000.0 in Q4 2023.
• Historically, Receivables - Other has averaged $776250.0 across 3 years, with a median of $6000.0 in 2023.
• On a YoY basis, Receivables - Other climbed as much as 51350.0% in 2025 and fell as far as 51350.0% in 2025.
• Year by year, Receivables - Other stood at $6000.0 in 2023, then changed by 0.0% to $6000.0 in 2024, then soared by 51350.0% to $3.1 million in 2025.
• Per Business Quant data, the three most recent Receivables - Other figures were $3.1 million in Q3 2025, $6000.0 in Q3 2024, and $6000.0 in Q2 2024.